NCT00188617View on ClinicalTrials.gov

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

PHASE2CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

November 30, 2009

Conditions

LUNG CANCER

Interventions

DRUG

GEFITINIB

250 mg once a day for 28 days before surgery

Trial Locations (1)

M5G 2C4

Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

University Health Network, Toronto

OTHER